This is a non-binding pipeline update with no concrete partnership, funding, or regulatory milestone. The stock may see speculative volume on the Ebola outbreak narrative, but the company's severe cash constraints ($4.1M) and going-concern risk dominate the fundamental outlook. Monitor for actual WHO platform inclusion or a funded collaboration agreement before assigning material value to this program.
Price Chart
Executive Summary
RedHill Biopharma announced it is actively discussing potential collaborations to advance its investigational oral drug opaganib for Ebola virus disease (EVD), including with the WHO's SOLIDARITY CORE clinical trial platform. The press release cites preclinical EVD activity from USAMRIID-funded studies and a 70.2% mortality reduction observed in a Phase 3 severe COVID-19 subgroup as supporting rationale. However, opaganib is not approved by any regulatory authority, inclusion in the WHO platform is not guaranteed, and the company faces severe financial distress with only $4.1M cash, a going-concern warning, and ongoing Nasdaq delisting risk per the prior 20-F filing.
Key Facts
- RedHill is actively discussing potential collaborations for opaganib in EVD, including the WHO SOLIDARITY CORE clinical trial platform.
- Opaganib is an investigational drug not approved by any regulatory authority; inclusion in the WHO platform cannot be guaranteed.
- Preclinical EVD activity was shown in USAMRIID-funded studies, but animal model results were mixed (20% vehicle survival vs. 10% opaganib in one model).
- A Phase 3 COVID-19 subgroup showed 70.2% mortality reduction (6.98% opaganib+SoC vs. 23.4% placebo+SoC, p=0.034) as add-on to remdesivir + corticosteroids.
- The company's 20-F (filed April 27, 2026) disclosed substantial doubt about going concern, only $4.1M cash, and Nasdaq delisting risk.
- A 424B5 filed May 7, 2026 authorized up to $1,587,708 in additional ADS sales under an at-the-market offering.
- Market cap is approximately $5M; ADS closed at $1.02 on May 6, 2026.
Financial Impact
No new funding or revenue disclosed. Prior 20-F reported $4.1M cash and $0.4M net loss in 2025. The 424B5 offering allows up to $1.59M in additional ATM sales, representing ~32% of market cap at current prices.
Risk Factors
- Opaganib may not be accepted into the WHO SOLIDARITY CORE platform or any other clinical program.
- Even if accepted, clinical efficacy in EVD is unproven; preclinical data showed mixed animal model results.
- Company has only $4.1M cash and a going-concern warning, limiting ability to fund new clinical trials without dilutive financing.
- Nasdaq delisting risk persists; ADS closed at $1.02 vs. $1.00 minimum bid requirement.
- Forward-looking statements caution that opaganib is not approved and may never achieve regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003040 |
| Document: 0001178913-26-003040-index-headers.html | 0001178913-26-003040 |
| Document: 0001178913-26-003040-index.html | 0001178913-26-003040 |
| Document: 0001178913-26-003040.txt | 0001178913-26-003040 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers